CDMO Catalent is considering adding two more manufacturing trains at its Madison facility due to anticipated demand for sub-5,000 L biomanufacturing. For Catalent’s fourth quarter FY2018, sales from its Biologics and Specialty Drug Delivery business stood at US$196 million (€168 million), twice that of the same period last year. The contract development and manufacturing organization (CDMO) attributed much of this increase to the acquisition of Cook Pharmica and the addition of a biomanufacturing facility in Bloomington, Indiana. However, management told…